CAR T-cell Therapy Market (By Product: Abecma, Breyanzi; By Disease Indication: Lymphoma, Leukemia, Multiple Myeloma; By End-use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The global CAR T-cell therapy market size was estimated at around USD 3.71 billion in 2023 and it is projected to hit around USD 30.25 billion by 2033, growing at a CAGR of 23.35% from 2024 to 2033. The CAR T-cell therapy market is driven by rising cancer prevalence, clinical success and regulatory approvals, and expanded indications.

Key Pointers

• North America dominated the market with the largest market share of 67% in 2023.
• Asia-Pacific expected to grow at the notable CAGR of 27.68% from 2024 to 2033.
• By Product, the Yescarta segment contributed the largest market share of 44% in 2023.
• By Disease Indication, the Lymphoma segment registered the maximum market share of 58% in 2023.
• By Disease Indication, the multiple myeloma is expected to expand at the highest CAGR of 22.07% from 2024 to 2033.
• By End-Use, the hospital segment had the largest market share of 58% in 2023.

CAR T-cell Therapy Market Overview

The CAR T-cell therapy market has witnessed remarkable growth in recent years, revolutionizing the treatment landscape for various cancers. This groundbreaking approach harnesses the power of the immune system by genetically modifying patients' T cells to target and destroy cancer cells. As we delve into the overview of the CAR T-cell therapy market, it becomes evident that this innovative treatment holds significant promise in reshaping the future of cancer care.

CAR T-cell Therapy Market Growth

The growth of the CAR T-cell therapy market is underpinned by several key factors. Firstly, the escalating incidence of cancer globally has stimulated a heightened demand for innovative and effective treatment modalities, positioning CAR T-cell therapy as a promising solution. Additionally, substantial investments by pharmaceutical companies in research and development have propelled the field forward, resulting in a surge of investigational therapies entering clinical trials. Moreover, the proactive stance of regulatory agencies in expediting the approval process for CAR T-cell therapies has instilled confidence in the market, facilitating quicker access to groundbreaking treatments for patients. These factors collectively contribute to the robust expansion of the CAR T-cell therapy market, ushering in a new era of advanced and personalized cancer care.

CAR T-cell Therapy Market Dynamics

Drivers

• Rising Cancer Prevalence: The increasing global incidence of cancer serves as a primary driver for the CAR T-cell therapy market. The therapy's capability to offer a targeted and personalized approach to cancer treatment aligns with the growing need for effective solutions against various malignancies.
• Investments in R&D: Significant investments by pharmaceutical companies and research institutions in research and development activities contribute to the advancement of CAR T-cell therapy. This financial commitment fosters innovation, accelerates clinical trials, and expands the therapeutic landscape.

Restraints

• Limited Target Spectrum: The current focus of CAR T-cell therapy on specific antigens restricts its applicability to a limited range of cancers. The therapy's effectiveness is contingent on identifying suitable targets, excluding certain tumors that lack identifiable antigens, thus limiting its broad-spectrum application.
• Complex Manufacturing Process: The intricate and labor-intensive manufacturing process involved in CAR T-cell therapy poses logistical challenges. The need for personalized cell processing, gene editing, and quality control measures contributes to production complexities, potentially hindering scalability.

Opportunities

• Expanded Indications and Target Spectrum: The continuous exploration of CAR T-cell therapy beyond hematological malignancies opens up opportunities to broaden its indications. Research efforts aimed at identifying novel antigens and expanding the target spectrum could lead to the development of therapies for a wider range of cancers.
• Next-Generation CAR Constructs: Ongoing advancements in CAR T-cell technology, including the development of next-generation CAR constructs, present opportunities for enhanced therapeutic efficacy and improved safety profiles. Innovations such as dual-targeting CARs and switchable CARs hold promise for addressing current limitations.

Product Insights

The Yescarta segment dominated the CAR T-cell therapy market in 2023, holding a significant share of 44%. This particular product segment is poised to be the fastest-growing during the forecast period. Yescarta, also known as axicabtagene ciloleucel, specifically targets the CD19 antigen. Prescribed primarily for large B-cell lymphoma cases where initial treatment proves ineffective, or cancer recurrence occurs within the first year of treatment, or when at least two treatments for follicular lymphoma have failed, Yescarta's strong market share is attributed to its demonstrated improvement in survival rates for adults with relapsed large B-cell lymphoma.

Anticipated to experience substantial growth in the CAR T-cell therapy market by 2033, the Carvykti segment is projected to achieve a remarkable CAGR of 15.69% during the period from 2023 to 2033. Carvykti operates as an autologous immunotherapy designed to identify and eliminate B cell maturation antigen (BCMA)-expressing cells. The product's exponential growth is facilitated by robust regulatory support, including clinical trials and approvals. Notably, the U.S. FDA approved Ciltacabtagene autoleucel on February 28, 2023, broadening its application, especially for patients dealing with multiple myeloma in relapsed or refractory conditions. Clinical trials have demonstrated compelling results, with approximately 98% of participants responding to treatment, and 78% showing no detectable signs of cancer in bone marrow or blood.

Disease Indication Insights

In 2023, the Lymphoma segment commanded the largest share, accounting for 58% of the CAR T-cell therapy market. This segment is also anticipated to be the fastest-growing application. The significant market dominance is attributed to the availability of various CAR-T drugs explicitly designed to target lymphoma. Notable examples such as Breyanzi, Kymirah, Tecartus, and Yescarta focus on the CD-19 antigen, facilitating the elimination of large B-cell lymphoma in both adults and children. The prevalence of lymphoma worldwide contributes to the dominance of CAR T-cell therapy in mitigating and eliminating life-threatening conditions. According to Globocon 2020, approximately 544,000 new cases of non-Hodgkin lymphoma were reported globally, with nearly 259,000 deaths recorded in the same year.

Multiple Myeloma is poised to be the second fastest-growing segment in the CAR T-cell therapy market by 2033, with an expected CAGR of 22.07% from 2024 to 2033. The global incidence of multiple myeloma has been on the rise, as highlighted in a report by Lancet Hematology 2020, indicating an age-standardized rate of 1.78 per 100,000 people worldwide. The research underscores a notable increase in overall incidence, particularly in countries with a relatively high population of men aged 50 or older. The continued support from the U.S. FDA in approving CAR T therapy drugs aims to reduce mortality rates associated with multiple myeloma. For example, in April 2021, idecabtagene vicleucel (Abecma) received U.S. FDA approval for individuals with multiple myeloma, especially those who have not responded to or have experienced a recurrence after four different cancer treatments.

End-use Insights

In 2023, the hospital segment dominated the CAR T-cell therapy industry, holding a substantial share of 58%. The prevalence of robust technology, well-equipped operating facilities, such as theatres, and the considerable purchasing power of hospitals globally contribute to this dominant market share. Hospitals that employ in-house CAR T processes can effectively reduce overall therapy costs, expanding their presence in this field. For instance, Sheba Hospital in Israel utilizes in-house processes, streamlining treatment time to less than 10 days and significantly cutting costs by at least 50%. The hospital has treated nearly 250 patients with CAR T therapy since 2015, drawing individuals from around the world.

Cancer Treatment Centers are projected to be the fastest-growing segment in the CAR T-cell therapy industry by 2033, with an anticipated CAGR of 24.28% from 2024 to 2033. This growth is attributed to the availability of diverse treatment options and patient-friendly amenities. Treating patients within their communities expands the overall reach of CAR T treatment. Additionally, strategic initiatives undertaken by prominent healthcare institutions will further enhance patient coverage. For example, in February 2023, the UVM Cancer Center in Vermont, U.S., announced the availability of a new CAR T-cell treatment for patients dealing with blood cancer.

Regional Insights

In 2023, North America held the largest share of the CAR T-cell therapy industry, representing approximately 67% of total market revenues. The region's dominant position is attributed to the presence of major companies, augmented government funding, ongoing research activities, and comprehensive coverage through various insurance policies. Given the considerable cost associated with CAR T therapies, averaging $400,000 and above, robust insurance policies play a crucial role in ensuring patient comfort and fostering market proliferation.

Asia-Pacific is forecasted to be the fastest-growing region in the CAR T-cell therapy industry by 2033, with an estimated CAGR of 27.68% from 2024 to 2033. This accelerated growth is fueled by the expanding patient pool in the region, coupled with statutory support for products and market players. Additionally, the market benefits from the concerted efforts of major players in developing technologically advanced therapies. For example, according to the Clinical Trials Database 2023, China has approximately 103 active clinical phases for CAR T Therapies, while Australia has nearly 5 studies in the pipeline for CAR T Therapy, indicating a robust landscape of ongoing research and development in the Asia-Pacific region.

CAR T-cell Therapy Market Key Companies

• Bristol-Myers Squibb Company
• Novartis AG
• Gilead Sciences, Inc.
• Johnson & Johnson Services, Inc.
• JW Therapeutics (Shanghai) Co., Ltd.
• bluebird bio, Inc.
• Merck & Co., Inc.
• Sangamo Therapeutics
• Sorrento Therapeutics, Inc.
• GSK plc.

CAR T-cell Therapy Market Segmentations:

By Product

• Abecma (idecabtagene vicleucel)
• Breyanzi (lisocabtagene maraleucel)
• Carvykti (ciltacabtagene autoleucel)
• Kymriah (tisagenlecleucel)
• Tecartus (brexucabtagene autoleucel)
• Yescarta (axicabtagene ciloleucel)
• Others

By Disease Indication

• Leukemia
• Lymphoma
• Multiple Myeloma
• Others

By End-Use

• Hospitals
• Cancer Treatment Centers

By Region

• North America
• Europe
• Asia Pacific
• Rest of World